{
    "ticker": "ATOS",
    "name": "Atossa Therapeutics, Inc.",
    "description": "Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for breast cancer and other breast-related diseases. Founded in 2009 and headquartered in Seattle, Washington, Atossa aims to address significant unmet medical needs in oncology. The company's lead product candidate, Endoxifen, is being developed to treat breast cancer and is currently in various stages of clinical trials. Atossa's research is driven by a commitment to advancing treatments that can improve patient outcomes. In addition to Endoxifen, the company is exploring other therapeutic options, including topical formulations designed to treat conditions associated with breast cancer. Atossa's mission is to empower patients and healthcare providers with effective treatment options while advancing scientific knowledge in the field of breast cancer. The company is dedicated to innovation, collaboration with healthcare professionals, and actively engaging with the breast cancer community to further its mission.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Seattle, Washington, USA",
    "founded": "2009",
    "website": "https://www.atossatherapeutics.com",
    "ceo": "Dr. Steven C. Quay",
    "social_media": {
        "twitter": "https://twitter.com/AtossaThera",
        "linkedin": "https://www.linkedin.com/company/atossa-therapeutics/"
    },
    "investor_relations": "https://www.atossatherapeutics.com/investors",
    "key_executives": [
        {
            "name": "Dr. Steven C. Quay",
            "position": "CEO"
        },
        {
            "name": "Dr. Eric A. H. H. A. G. Quay",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Endoxifen",
                "Topical Formulations"
            ]
        }
    ],
    "seo": {
        "meta_title": "Atossa Therapeutics, Inc. | Innovative Breast Cancer Treatments",
        "meta_description": "Atossa Therapeutics, Inc. is dedicated to developing innovative therapies for breast cancer and related diseases. Learn about their ongoing clinical trials and research.",
        "keywords": [
            "Atossa Therapeutics",
            "Breast Cancer",
            "Endoxifen",
            "Biopharmaceuticals",
            "Clinical Trials"
        ]
    },
    "faq": [
        {
            "question": "What does Atossa Therapeutics focus on?",
            "answer": "Atossa Therapeutics focuses on developing innovative therapies for breast cancer and other breast-related diseases."
        },
        {
            "question": "Who is the CEO of Atossa Therapeutics?",
            "answer": "The CEO of Atossa Therapeutics is Dr. Steven C. Quay."
        },
        {
            "question": "Where is Atossa Therapeutics headquartered?",
            "answer": "Atossa Therapeutics is headquartered in Seattle, Washington, USA."
        },
        {
            "question": "What is Atossa's lead product candidate?",
            "answer": "Atossa's lead product candidate is Endoxifen, which is being developed to treat breast cancer."
        },
        {
            "question": "When was Atossa Therapeutics founded?",
            "answer": "Atossa Therapeutics was founded in 2009."
        }
    ],
    "competitors": [
        "AMGN",
        "NVS",
        "MRNA",
        "BMY"
    ],
    "related_stocks": [
        "PFE",
        "JNJ",
        "GILD",
        "ABBV"
    ]
}